Key takeaways
- We found no peptide medicine approved to build muscle in healthy people, and a 2024 review states that FDA has approved no drug for sarcopenia.
- FDA staff recorded in 2026 that TB-500, BPC-157 and MOTS-c are promoted online for uses that include muscle; the published muscle studies we found are in rats and mice. FDA staff found no article in which TB-500 was given to people; a later 2026 report describes three patients given it with BPC-157 and other agents, without a control group.
- Antibodies that block the myostatin–activin pathway have reached people: apitegromab is FDA-approved for spinal muscular atrophy only, and in a trial of 180 older adults with sarcopenia the investigational antibody bimagrumab raised lean mass more than placebo, but physical performance did not differ.
- WADA prohibits every compound on this page at all times: BPC-157 (S0), TB-500 (S2.3), apitegromab, bimagrumab and follistatin (S4.3) and MOTS-c (S4.4.1), in the 2026 and 2027 Lists.
- Australia’s Poisons Standard (October 2026) lists BPC-157, TB-500, thymosin β4 and follistatin in Schedule 4 and Appendix D.
01Is any peptide approved for muscle growth?
Not that we found. We found no peptide medicine approved to build muscle in healthy people. A 2024 review of sarcopenia, the loss of muscle mass with age, states that “there are currently no drugs approved by the Food and Drug Administration for sarcopenia”. On 18 November 2026 no US drug label in FDA’s database listed sarcopenia in its indications, no label listed “muscle growth”, and the UK’s electronic medicines compendium returned nothing for sarcopenia. The one medicine we found approved that blocks myostatin, apitegromab (Isembyld), is an antibody, not a peptide, and FDA approved it on 11 September 2026 for spinal muscular atrophy in patients aged 2 and over who already receive an SMN2-targeted treatment: see below.
What is sold online as “peptides for muscle growth” is a different set of compounds. In its 2026 reviews for its compounding advisory committee, FDA staff recorded that TB-500, BPC-157 and MOTS-c are promoted online for a range of uses, muscle among them. None of the three is an FDA-approved medicine: Drugs@FDA lists no product containing any of them (18 Nov 2026).
Anabolic steroids are a different class of compound: see are peptides steroids? This page does not cover compounds that act on growth hormone.
02Which compounds have muscle studies, and in which models?
Each compound, the highest-tier muscle study we found, and its status, dated 18 November 2026. Tiers follow our evidence grades; sources are at the end of the page.
| Compound | What it is | Highest-tier muscle study we found | Tier | Status: US · UK · Australia · sport | What we don’t know |
|---|---|---|---|---|---|
| Apitegromab (Isembyld) | Monoclonal antibody that targets the precursor forms of myostatin; not a peptide | Study 1 on its US label: randomised, double-blind, placebo-controlled; 188 patients aged 2 to 21 with spinal muscular atrophy, all on an SMN2-targeted treatment; about 1 year; motor function (HFMSE) measured | T1, approved for SMA only | US: approved 11 Sep 2026 (BLA 761463), spinal muscular atrophy only · UK: no emc entry · AU: no TGA Product Information found · WADA: S4.3 (named) | Anything outside spinal muscular atrophy: its label covers no other use |
| Bimagrumab | Investigational antibody that blocks activin type II receptors; not a peptide | Rooks et al., JAMA Network Open 2020: randomised, double-blind, placebo-controlled; 180 adults aged 70 and over with sarcopenia; 6 months | T1, investigational | US: no product in Drugs@FDA · UK: no emc entry · WADA: prohibited at all times, class S4.3 (named) | Whether added lean mass improves function: in that trial, physical performance did not differ from placebo |
| Follistatin (sold online as “follistatin 344”) | Protein that binds myostatin and activin | Lee and McPherron, PNAS 2001: transgenic mice made to produce extra follistatin in muscle; muscle mass measured. Mendell et al., Molecular Therapy 2015: gene transfer (AAV1.FS344), uncontrolled phase 1/2a, 6 patients with Becker muscular dystrophy | T3; T2 for the gene-transfer study | US: no product in Drugs@FDA · UK: no emc entry · AU: Schedule 4 and Appendix D, clause 5 (Poisons Standard Oct 2026) · WADA: S4.3 (named) | What a manufactured follistatin product does in people: the human study used gene transfer, not the protein |
| BPC-157 | Synthetic peptide of 15 amino acids | Staresinic et al., Journal of Orthopaedic Research 2006: rats with a cut quadriceps muscle; strength, walking function and microscopy measured. A phase 2 placebo-controlled trial in hamstring strain (120 planned) is recruiting | T3 | US: no product in Drugs@FDA · UK: no emc entry · AU: Schedule 4 and Appendix D, clause 5 · WADA: S0 (named) | Any effect on muscle in people: the hamstring trial has no results |
| TB-500 and thymosin β4 | TB-500: a 7-amino-acid fragment of thymosin β4 in FDA’s documents. Thymosin β4: a 43-amino-acid protein | Spurney et al., PLoS One 2010: thymosin β4 (the full protein) given to exercised mdx mice, a model of Duchenne muscular dystrophy, for 6 months; regenerating fibres, grip strength, heart function and fibrosis measured. FDA staff found no article in which TB-500 was given to people; a later 2026 report describes three patients given it with BPC-157 and other agents, without a control group | T3 | US: no product in Drugs@FDA · UK: no emc entry for thymosin · AU: both in Schedule 4 and Appendix D, clause 5 · WADA: S2.3 (“Thymosin-β4 and its derivatives e.g. TB-500”) | Any effect on muscle in people. The one registered TB-500 trial studies heart disease, not muscle |
| MOTS-c | Mitochondrial-derived peptide of 16 amino acids | Reynolds et al., Nature Communications 2021: treadmill running in mice aged 2, 12 and 22 months (5 to 19 per group); grip strength and walking tests in old mice | T3 | US: FDA staff say it is not a component of any FDA-approved drug · UK: no emc entry · AU: not named in the Poisons Standard (Oct 2026); we found no TGA statement applying any of its group entries to it and draw no scheduling conclusion of our own · WADA: S4.4.1 (named) | Any effect in people: no published study has given it to people |
03What has myostatin-pathway research measured, in animals and in people?
The pathway. Myostatin is a growth factor that, in the words of a 2001 paper, “acts as a negative regulator of skeletal muscle mass”. It binds activin type II receptors. Blocking that signal is the idea behind the antibodies below.
Apitegromab (approved for spinal muscular atrophy only). FDA approved Isembyld (apitegromab) on 11 September 2026. Its label describes a fully human monoclonal antibody that “targets proforms of myostatin”, indicated for spinal muscular atrophy in patients aged 2 and over who are already receiving an SMN2-targeted treatment. The label’s main trial randomised 188 patients aged 2 to 21 with spinal muscular atrophy to apitegromab or placebo for about a year and measured the change in a motor-function scale (HFMSE). The label warns that it “may increase the risk of fractures, including serious fractures”, and lists upper respiratory tract infections, vomiting, cough, headache and hypersensitivity among its most common adverse reactions. It is a prescription medicine for one disease, not a muscle-building product, and research-grade material sold online is not this medicine.
Follistatin (T3). In lab experiments, Lee and McPherron (PNAS, 2001) found that follistatin inhibited myostatin binding to its receptor. They then bred transgenic mice that made extra follistatin in muscle and measured their muscle mass. In 2015 a phase 1/2a study used gene transfer (AAV1.FS344) to deliver follistatin in six patients with Becker muscular dystrophy, with no control group, and measured the six-minute walk distance. Neither study gave people a manufactured follistatin protein.
Bimagrumab (T1, investigational). Bimagrumab is a fully human monoclonal antibody against activin type II receptors, not a peptide, and it is not approved. In a randomised, placebo-controlled trial of 180 adults aged 70 and over with sarcopenia, with adequate diet and home-based exercise in both groups, lean body mass rose 7% with bimagrumab and 1% with placebo over 6 months, but the primary measure, a physical-performance score, improved in both groups with no significant difference between them (Rooks et al., 2020). In RESILIENT, 251 adults with inclusion body myositis, a muscle disease, the six-minute walk distance at 52 weeks did not differ between bimagrumab and placebo; muscle spasms and diarrhoea were more frequent with bimagrumab, and serious adverse events were reported in 17% to 33% of the bimagrumab groups and 32% of the placebo group (Hanna et al., 2019). In a 2026 phase 2 obesity trial in 507 adults, the common adverse events of bimagrumab included muscle spasms, diarrhoea and acne.
Sport. WADA’s class S4.3, “agents preventing activin receptor IIB activation”, names apitegromab, bimagrumab and follistatin among its examples. They are prohibited at all times.
04What have BPC-157, TB-500 and MOTS-c muscle studies measured, and what do regulators say?
FDA staff found these three promoted online for muscle, among other uses. Their muscle studies are in animals; we describe the models and what was measured, not the authors’ findings.
BPC-157 (T3). In muscle-injury models, researchers cut the quadriceps muscle of rats (2006) or crushed the gastrocnemius muscle (2008), gave BPC-157, and measured healing by strength testing, walking function and microscopy. A 2025 systematic review of BPC-157 in orthopaedic sports medicine found 36 eligible studies, 35 of them preclinical, in models of muscle, tendon, ligament and bone injury. In people, a randomised, double-blind, placebo-controlled phase 2 trial in acute hamstring strain, planned for 120 participants, began in February 2026 and is recruiting; its primary outcomes are time to return to sport and the injury volume on MRI. It has no results. An uncontrolled study of a commercial product containing BPC-157, made by the study’s sponsor, in 40 physically active adults was completed in November 2025; it lists exercise-induced muscle damage among its conditions, measured blood markers of inflammation and self-reported swelling, and has posted no results. FDA staff, reviewing BPC-157 in 2026, found “insufficient clinical safety information to characterize the safety profile”, and wrote that as a peptide “administered through a parenteral or nasal” route it “may pose a significant risk for immunogenicity”. More: the BPC-157 guide.
TB-500 and thymosin β4 (T3). FDA staff wrote in 2026 that after a literature search “no articles were found in which TB-500 was administered to humans”. They concluded that “potential safety risks associated with the use of these substances in humans are unknown”, and that for the routes proposed in its nomination TB-500 “may pose a significant risk for immunogenicity”. A later report (2026) describes three dental patients with nerve injury who received TB-500 together with BPC-157 and other agents; with no control group, its authors write that causality “cannot be established”. The muscle study we found used the full 43-amino-acid protein, not TB-500: exercised mdx mice, a model of Duchenne muscular dystrophy, were given thymosin β4 for 6 months, and the researchers counted regenerating muscle fibres and measured grip strength, heart function and fibrosis (2010). The only registered TB-500 trial, a phase 1/2 study planned for 80 adults, is in stable atherosclerotic cardiovascular disease and measures adverse events. More: the TB-500 guide.
MOTS-c (T3). The group that described MOTS-c measured treadmill running in mice aged 2, 12 and 22 months (5 to 19 per group), and grip strength and walking tests in old mice (Reynolds et al., 2021). No published study has given MOTS-c to people. FDA staff found “a lack of evidence to evaluate the effectiveness” of MOTS-c for its nominated uses, which included “muscle/fat metabolism”, because the studies were “limited to in-vitro and in-vivo rodent models”, and they wrote that “potential safety risks associated with the use of MOTS-c in humans are unknown”. FDA’s compounding safety-risk page (content current 22 April 2026) says compounded drugs containing MOTS-c “may pose significant risk for immunogenicity for certain routes of administration”. More: the MOTS-c guide.
05How does WADA classify these compounds?
WADA’s Prohibited List names each compound on this page, and each is prohibited at all times, in and out of competition, in the 2026 and 2027 Lists.
- S0, non-approved substances: BPC-157, named among examples of substances “with no current approval by any governmental regulatory health authority for human therapeutic use”.
- S2.3, growth factors and growth factor modulators: “Thymosin-β4 and its derivatives e.g. TB-500”, and other growth factors “affecting muscle, tendon or ligament protein synthesis/degradation”.
- S4.3, agents preventing activin receptor IIB activation: apitegromab, bimagrumab and follistatin, among others.
- S4.4.1, metabolic modulators: MOTS-c, among activators of AMPK.
WADA’s explanatory note to the 2027 List adds: “Even if a peptide is not specifically named on the List, utmost caution should be taken as it may still be prohibited and may be harmful to health.” More: peptides and anti-doping.
06What we don’t know about peptides and muscle growth
- Whether BPC-157, TB-500 or MOTS-c changes muscle in people. No controlled trial of any of them in muscle has published results. The placebo-controlled BPC-157 hamstring trial is recruiting, and an uncontrolled BPC-157 study that lists exercise-induced muscle damage among its conditions has posted no results.
- Whether more lean mass means better function. In bimagrumab’s sarcopenia trial, lean mass rose more than with placebo, but physical performance did not differ.
- What a manufactured follistatin product does in people. The human study we found used gene transfer.
- What blocking myostatin does in healthy people. The trials on this page were in people with sarcopenia, muscle disease, spinal muscular atrophy or obesity.
- What a vial sold online contains. Only a test of that sample can say.
Why we publish no doses for any compound: why we don’t publish doses.
This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not medical or legal advice.